• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Biobeat Technologies Names Raymond W. Cohen as Chairman of the Board of Directors

    8/21/25 7:00:00 AM ET
    $KMTS
    $NSPR
    $RXST
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $KMTS alert in real time by email

    Biobeat Technologies Ltd, a medical device company that has developed a wearable cuff-less ambulatory blood pressure monitoring system that records and analyzes numerous physiological parameters, today announced the appointment of Raymond W. Cohen as its Chairman of the Board of Directors.

    Biobeat developed and has received FDA clearance for an easy-to-apply "patch" device that can collect, record and transmit patient data to a cloud-based data center for AI-aided analysis and reporting of physiological parameters, including continuous cuff-less ambulatory blood pressure (ABPM), Sp02, respiration rate, pulse rate, heart rate variability, ECG, temperature and cardiac output.

    "We welcome Raymond W. Cohen as our new Chairman," said Arik Ben Ishay, co-founder and CEO of Biobeat. "Ray's extensive track record in leading, financing and scaling medical technology companies will be invaluable as we look to capitalize on our unique ambulatory technology."

    Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of life science industry experience. He was the co-founder and CEO of publicly traded Axonics, Inc., a global leader in implantable neuromodulation devices that completed its initial public offering in late 2018. Under his leadership, Axonics generated over $1 billion in revenue within four years of its commercial launch, became profitable, earned recognition as the fastest-growing technology company in North America, and was acquired by Boston Scientific in November 2024 for $3.7 billion. In March 2025, Mr. Cohen, as chairman of SoniVie, Ltd., an Israeli clinical stage renal denervation company, led the sale of SoniVie to Boston Scientific for $600 million.

    "Biobeat has accomplished what has been an elusive goal for many – a clinically validated and FDA cleared cuff-less ABPM that has the potential to change the use paradigm for measuring ambulatory blood pressure. We see numerous applications for this technology in the new field of renal denervation (RDN) as well as long term monitoring of post-cardiac procedure and CHF patients following discharge from the hospital," said Mr. Cohen. "I look forward to collaborating with the management team to support the company's mission to change the way patients are monitored."

    Cohen currently serves on the boards of several public and venture capital backed innovative healthcare companies, including Kestra Medical Technologies (NASDAQ:KMTS); InspireMD (NASDAQ:NSPR); RxSight (NASDAQ:RXST), privately held Nalu Medical as chairman, Archimedes Vascular as chairman, Tulavi Medical as vice chairman, and Spectrum Vascular as an independent director. Mr. Cohen also serves as a venture partner with Paris-based Andera Partners and Beijing-based Sherpa Capital Partners.

    About Biobeat Technologies, Ltd

    Biobeat based in Israel with offices in Boca Raton Florida, is a privately held company that has developed wearable, non-invasive cuffless ambulatory blood pressure monitoring technology that enables continuous, blood pressure measurements, respiratory rate, Sp02, ECG, pulse rate, body temperature, stroke volume, cardiac output, systemic vascular resistance and other key physiological parameters. By comparison, unlike traditional ABPM system, Biobeat offers a cuff-less small unobtrusive "patch" device with enhanced patient comfort, especially during sleep while collecting and transmitting real time data to a mobile app. Biobeat's products are 510(k) cleared by the US Food & Drug Administration.

    For more information: www.bio-beat.com

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250821891096/en/

    Media Contact:

    Sharon Dayan

    VP Marketing

    [email protected]

    Get the next $KMTS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KMTS
    $NSPR
    $RXST

    CompanyDatePrice TargetRatingAnalyst
    RxSight Inc.
    $RXST
    7/15/2025$9.00Overweight → Equal-Weight
    Morgan Stanley
    RxSight Inc.
    $RXST
    7/10/2025$9.00Buy → Hold
    Jefferies
    RxSight Inc.
    $RXST
    7/9/2025Outperform → Perform
    Oppenheimer
    RxSight Inc.
    $RXST
    7/9/2025$9.00Overweight → Equal Weight
    Wells Fargo
    RxSight Inc.
    $RXST
    7/9/2025Buy → Neutral
    BTIG Research
    RxSight Inc.
    $RXST
    5/19/2025$25.00Equal Weight → Overweight
    Wells Fargo
    RxSight Inc.
    $RXST
    4/15/2025$18.00Neutral
    Piper Sandler
    RxSight Inc.
    $RXST
    4/9/2025$16.00Buy → Neutral
    UBS
    More analyst ratings

    $KMTS
    $NSPR
    $RXST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Commercial Officer Ford Alfred J Jr bought $340,000 worth of shares (20,000 units at $17.00), increasing direct ownership by 68% to 49,412 units (SEC Form 4)

    4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/15/25 4:30:46 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Amendment: Officer Umberger Traci S bought $229,500 worth of shares (13,500 units at $17.00), increasing direct ownership by 11% to 134,336 units (SEC Form 4)

    4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/15/25 4:17:34 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Director Cohen Raymond W bought $289,000 worth of shares (17,000 units at $17.00) and was granted 10,909 shares, increasing direct ownership by 215% to 40,903 units (SEC Form 4)

    4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/8/25 5:38:22 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $KMTS
    $NSPR
    $RXST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025

    ALISO VIEJO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the third quarter of 2025 after the market close on Wednesday, November 5, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 6619966. The call will also be broadcast live in listen-only mode via a link on the company's investor relations

    10/22/25 4:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    InspireMD to Announce Third Quarter 2025 Financial Results

    MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by registering below. A replay of the webin

    10/21/25 4:05:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MIAMI, Oct. 08, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to three (3) new non-executive employees in the aggregate amount of 40,513 shares of restricted stock (the "Inducement Grants") outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of October 7, 2025, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants were granted

    10/8/25 8:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $KMTS
    $NSPR
    $RXST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Roubin Gary S was granted 48,000 shares, increasing direct ownership by 8% to 656,425 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    10/9/25 4:05:23 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Officer Goldshleger Ilya exercised 23,445 shares at a strike of $4.27, increasing direct ownership by 55% to 65,691 units (SEC Form 4)

    4 - RxSight, Inc. (0001111485) (Issuer)

    9/26/25 4:07:58 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    New insider Dearen Danny L. claimed ownership of 58,017 shares (SEC Form 3)

    3 - InspireMD, Inc. (0001433607) (Issuer)

    9/24/25 4:00:13 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $KMTS
    $NSPR
    $RXST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RxSight downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded RxSight from Overweight to Equal-Weight and set a new price target of $9.00

    7/15/25 8:39:07 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight downgraded by Jefferies with a new price target

    Jefferies downgraded RxSight from Buy to Hold and set a new price target of $9.00

    7/10/25 8:36:38 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight downgraded by Oppenheimer

    Oppenheimer downgraded RxSight from Outperform to Perform

    7/9/25 8:19:00 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $KMTS
    $NSPR
    $RXST
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Kestra Medical Technologies Ltd.

    SCHEDULE 13G/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Subject)

    10/7/25 3:49:26 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    InspireMD Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - InspireMD, Inc. (0001433607) (Filer)

    9/17/25 8:00:33 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Kestra Medical Technologies Ltd.

    10-Q - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

    9/12/25 4:17:17 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $KMTS
    $NSPR
    $RXST
    Leadership Updates

    Live Leadership Updates

    View All

    Kestra Appoints Timothy Moran as Chief Business Officer, Strengthening Leadership Team for Next Stage of Growth

    KIRKLAND, Wash., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Timothy Moran as Chief Business Officer, effective November 3. In this role, Mr. Moran will oversee business strategy, corporate business development, payor engagement and contracting, reimbursement strategy, and revenue cycle management. "I am pleased to welcome Tim as our Chief Business Officer," said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. "With extensive expertise in cardiac and heart failure innovation, Tim is well positioned to join Kestra at this i

    10/7/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

    MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and

    9/17/25 8:00:00 AM ET
    $BBNX
    $NSPR
    Medical/Dental Instruments
    Health Care

    Kestra Medical Technologies Appoints Dr. Elizabeth Kwo to Board of Directors

    KIRKLAND, Wash., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Elizabeth Kwo, M.D. as an independent director to its board following her election at the company's annual general meeting of shareholders held earlier this month. "I am pleased to welcome Dr. Kwo to the Kestra board of directors," said Brian Webster, President and CEO of Kestra Medical Technologies. "As a physician, healthcare executive, and entrepreneur, she brings extensive experience building and scaling digital health platforms and advancing data-driven care models to improve patient outcomes.

    9/17/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $KMTS
    $NSPR
    $RXST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by InspireMD Inc.

    SC 13G - InspireMD, Inc. (0001433607) (Subject)

    12/4/24 4:31:06 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/24 6:35:20 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by RxSight Inc.

    SC 13G/A - RxSight, Inc. (0001111485) (Subject)

    11/14/24 5:46:12 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $KMTS
    $NSPR
    $RXST
    Financials

    Live finance-specific insights

    View All

    RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025

    ALISO VIEJO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the third quarter of 2025 after the market close on Wednesday, November 5, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 6619966. The call will also be broadcast live in listen-only mode via a link on the company's investor relations

    10/22/25 4:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    InspireMD to Announce Third Quarter 2025 Financial Results

    MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by registering below. A replay of the webin

    10/21/25 4:05:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results

    KIRKLAND, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today reported financial results for the first quarter fiscal 2026, which ended July 31, 2025. Financial Highlights Generated revenue of $19.4 million in Q1 FY26, an increase of 52% compared to the prior year period.Expanded gross margin to 45.7% in Q1 FY26 compared to 32.9% in the prior year period.Increased FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. "We had a strong start to fiscal 2026, with our sustained commercial momentum generating revenue growth of over 50% in the first quarter," sai

    9/11/25 4:01:00 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care